参考文献/References:
[1] Kerr JR, Wyllie AH, Currie AR. Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics[J]. Br J Cancer, 1972, 26(4):239-257.
[2] 高超, 华子春. 细胞凋亡检测方法新进展[J]. 中国细胞生物学学报, 2011, 33(5):564-569. DOI:10.1007/s11883-010-0105-8.Gao C, Hua Z C. Progress on detection of apoptosis[J]. Chin J Cell Bio, 2011, 33(5):564-569.
[3] Kemerink GJ, Liu X, Kieffer D, et al. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application[J]. J Nucl Med, 2003, 44(6):947-952.
[4] Guo MF, Zhao Y, Tian R, et al. In vivo 99mTc-HYNIC-annexin V imaging of early tumor apoptosis in mice after single dose irradiation[J]. J Exp Clin Cancer Res, 2009, 28(1):136-144. DOI:10.1186/1756-9966-28-136.
[5] Kartachova M, Haas RL, Olmos RA, et al. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy:visual analysis in relation to treatment response[J]. Radiother Oncol, 2004, 72(3):333-339. DOI:10.1016/j. radonc. 2004. 07. 008.
[6] Kartachova M, Van Zandwijk N, Burgers S, et al. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer[J]. J Clin Oncol, 2007, 25(18):2534-2539. DOI:10.1200/JCO. 2006. 10.1337.
[7] van de Wiele C, Lahorte C, Vermeersch H, et al. Quantitative tumor apoptosis imaging using technetium-99m-HYNIC annexin V single photon emission computed tomography[J]. J Clin Oncol, 2003, 21(18):3483-3487. DOI:10.1200/JCO.2003.12.096.
[8] 孙树汉, 王俊霞, 陈蕊雯, 等. 囊虫病诊断用抗原编码cDNA的分子克隆[J]. 中国寄生虫学与寄生虫病杂志, 1997, 15(1):15-20.Sun SH, Wang JX, Chen RW, et al. MoIecuIar cIoning of cDNA encoding immunodiagnostic antigens of cysticercosis[J]. Chin J Parasitol Parasitic Dis, 1997, 15(1):15-20.
[9] Hongli Y, Shuhan S, Ruiwen C, et al. CIoning and functionaI identification of a novel annexin subfamiIy in Cysticercus cellulosae[J]. Mol Biochem Parasitol, 2002, 119(1):1-5.
[10] 罗全勇, 陈泽泉, 陈立波, 等. 99Tcm-Annexin B1探测荷瘤鼠化疗后肿瘤细胞凋亡的实验观察[J]. 中华肿瘤防治杂志, 2008, 15(20):1524-1527, 1539. DOI:10.3969/j.issn.1673-5269.2008. 20.002.Luo QY, Chen ZQ, Chen LB, et al. Detection of tumor cell apoptosis induced by chemotherapy with 99Tcm-Annexin B1[J]. Chin J Cancer Prev Treat, 2008, 15(20):1524-1527, 1539.
[11] 王峰, 方纬, 季顺东, 等. 锝标突触结合蛋白ⅠC2A片段探测肺癌凋亡的实验研究[J]. 中华肿瘤杂志, 2007, 29(5):351-354. DOI:10. 3760/j. issn:0253-3766.2007.05.008.Wang F, Fang W, Ji SD, et al. Technetium-99m labeled synaptotagmin Ⅰ C2A detection of paclitaxel-induced apoptosis in non-small cell lung cancer[J]. Chin J Oncol, 2007, 29(5):351-354.
[12] Wang F, Fang W, Zhao M, et al. Imaging paclitaxel(chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I:a preliminary study[J]. Nucl Med Biol, 2008, 35(3):359-364. DOI:10.1016/j.nucmedbio.2007.12.007.
[13] Zhao M, Li Z, Bugenhagen S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe[J]. J Nucl Med, 2008, 49(8):1345-1352. DOI:10. 2967/jnumed. 107. 048603.
[14] Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET[J]. Appl Radiat Isot, 2003, 58(2):201-207.DOI:10.1016/S0969-8043(02)00302-0
[15] Hu S, Kiesewetter DO, Zhu L, et al. Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V[J]. Mol Imaging Biol, 2012, 14(6):762-770. DOI:10.1007/s11307-012-0551-5.
[16] Qin H, Zhang MR, Xie L, et al. PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with(18)F(-)Labeled recombinant human His10-annexin V[J]. Am J Nucl Med Mol Imaging, 2015, 5(1):27-37.
[17] 赵庆, 章英剑, 王芳, 等. 18F-SFB-Annexin B1探测细胞凋亡实验研究[J]. 中华核医学杂志, 2011, 31(2):112-116. DOI:10.3760/cma.j.issn.0253-9780. 2011. 02. 010.Zhao Q, Zhang YJ, Wang F, et al. Evaluation of 18F-SFB-Annexin B1 in detecting apoptosis[J]. Chin J of Nucl Med, 2011, 31(2):112-116.
[18] Wang MW, Wang F, Zheng YJ, et al. An in vivo molecular imaging probe 18F-Annexin B1 for apoptosis detection by PET/CT:preparation and preliminary evaluation[J]. Apoptosis, 2013, 18(2):238-247. DOI:10.1007/s10495-012-0788-0.
[19] Wang F, Fang W, Zhang MR, et al. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I[J]. J Nucl Med, 2011, 52(4):592-599. DOI:10. 2967/jnumed.110.081588.
[20] Cohen A, Shirvan A, Levin G, et al. From the Gla domain to a novel small-molecule detector of apoptosis[J]. Cell Res, 2009, 19(5):625-637. DOI:10.1038/cr.2009.17.
[21] H?glund J, Shirvan A, Antoni G, et al. 18F-ML-10, a PET tracer for apoptosis:first human study[J]. J Nucl Med, 2011, 52(5):720-725. DOI:10. 2967/jnumed.110.081786.
[22] Allen AM, Ben-Ami M, Reshef A, et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10[J]. Eur J Nucl Med Mol Imaging, 2012, 39(9):1400-1408. DOI:10.1007/s00259-012-2150-8.
[23] Yao S, Hu K, Tang G, et al. Molecular PET imaging of cyclophosphamide induced apoptosis with 18F-ML-8[J]. Biomed Res Int, 2015, (2015):1-10. DOI:10.1155/2015/317403.
[24] Podichetty AK, Wagner S, Schr?er S, et al. Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis[J]. J Med Chem, 2009, 52(11):3484-3495. DOI:10.1021/jm8015014.
[25] Nguyen QD, Lavdas I, Gubbins J, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging[J]. Clin Cancer Res, 2013, 19(14):3914-3924. DOI:10.1158/1078-0432.CCR-12-3814.
[26] Su H, Chen G, Gangadharmath U, et al. Evaluation of[(18)F]-CP18 as a PET imaging tracer for apoptosis[J]. Mol Imaging Biol, 2013, 15(6):739-747. DOI:10.1007/s11307-013-0644-9.
[27] Xia CF, Chen G, Gangadharmath U, et al. In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer[18F]-CP18 for PET imaging of apoptosis in tumors[J]. Mol Imaging Biol, 2013, 15(6):748-757. DOI:10.1007/s11307-013-0646-7.
[28] Shen B, Jeon J, Palner M, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-triggered nanoaggregation probe[J]. Angew Chem Int Ed Engl, 2013, 52(40):10511-10514. DOI:10.1002/anie. 201303422.
[29] Hight MR, Cheung YY, Nickels ML, et al. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells[J]. Clin Cancer Res, 2014, 20(8):2126-2135. DOI:10.1158/1078-0432. CCR-13-2444.
[30] 张宝石, 周乃康, 王卉, 等. 18F-FP-peptide用于化疗后肿瘤细胞凋亡显像[J]. 中华核医学与分子影像杂志, 2012, 32(2):84-89. DOI:10.3760/cma. j. issn. 2095-2848.2012.02.002.Zhang BS, Zhou NK, Wang H, et al. Imaging of apoptosis with 18F-FP-peptide focused on the evaluation of tumor response to chemotherapy[J]. Chin J Nucl Med Mol Imaging, 2012, 32(2):84-89.
[31] 柳曦, 张宝石, 周乃康, 等. 凋亡显像早期检测肿瘤化疗疗效的实验研究[J]. 功能与分子医学影像学杂志:电子版, 2014, 3(2):11-15.Liu X, Zhang BS, Zhou NK, et al. Early detection of tumor response to chemotherapy by molecular apoptosis imaging:An experimental study[J/OL]. Funct Mol Med Imaging(Electronic Edition), 2014, 3(2):11-15[2015-09-10] http://www.cqvip.com/QK/71591X/201402/662035213.html.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]邢宇,赵新明.放射性核素标记HER2亲和体分子探针精准诊疗的研究进展[J].国际放射医学核医学杂志,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
Xing Yu,Zhao Xinming.Advances in radionuclide-labeled HER2 affibody molecular probes for precise diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):139.[doi:10.3760/cma.j.issn.1673-4114.2016.02.011]
[4]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[5]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[6]孙芳芳,张欣.uPAR放射性核素靶向显像研究进展[J].国际放射医学核医学杂志,2016,40(3):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
Sun Fangfang,Zhang Xin.Research progress of uPAR-targeted nuclear imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):230.[doi:10.3760/cma.j.issn.1673-4114.2016.03.013]
[7]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(2):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[8]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[9]任佳忠,李永梅,刘岩,等.99Tcm-MDP骨显像胸部异常放射性摄取的原因分析[J].国际放射医学核医学杂志,2016,40(6):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
Jiazhong,Li Yongmei,Liu Yan,et al.Reasons for the abnormal 99Tcm-MDP uptake in the thoracic tissue on bone scintigraphy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):459.[doi:10.3760/cma.j.issn.1673-4114.2016.06.011]
[10]马彦云,张辉.磁共振体素内不相干运动扩散加权成像的原理及应用进展[J].国际放射医学核医学杂志,2016,40(6):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
Ma Yanyun,Zhang Hui.The basic principle and application progress of intravoxel incoherent motion imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):469.[doi:10.3760/cma.j.issn.1673-4114.2016.06.013]
[11]杨明福,李前伟.肿瘤血管内皮生长因子受体核素显像研究现状[J].国际放射医学核医学杂志,2010,34(1):19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.005]
YANG Ming-fu,LI Qian-wei.Review present study on vascular endothelial growth factor receptor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):19.[doi:10.3760/cma.j.issn.1673-4114.2010.01.005]
[12]高玉婷,王自正.生长抑素类似物介导靶向显像及治疗的研究现状和进展[J].国际放射医学核医学杂志,2009,33(6):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
GAO Yu-ting,WANG Zi-zheng.The development of somatostatin analogues mediated tumor targeting and therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):330.[doi:10.3760/cma.j.issn.1673-4114.2009.06.003]
[13]汪永红,陈文新,何品玉.肿瘤表皮生长因子受体的分子显像研究[J].国际放射医学核医学杂志,2009,33(4):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
WANG Yong-hong,CHEN Wen-xin,HE Pin-yu.Tumor epidermal growth factor receptor molecular imaging research[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):204.[doi:10.3760/cma.j.issn.1673-4114.2009.04.004]
[14]王秀娟,李险峰.生长抑素受体肿瘤显像的临床应用及研究进展[J].国际放射医学核医学杂志,2006,30(4):217.
WANG Xiu-juan,LI Xian-feng.Clinical application and progress of somatostatin receptor imaging in diagnosis of cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(2):217.